Advisory Boards

Jeanne L. Becker, PhD
Dr. Becker is a scientific consultant for ChemoSen3D, who was the founding President, CEO and Executive Director of CASIS. Dr. Becker also served as Chief Science Officer for Astrogenetix, Inc., and was part of the research team using the conditions of microgravity to uncover novel targets for the development of bacterial vaccines and therapeutics. Dr. Becker has held faculty positions at Baylor College of Medicine and the University of South Florida College of Medicine.

J. Houston Miller, PhD
Prof. Miller is a Professor of Chemistry at GWU. His distinguished scientific career includes over 100 scientific publications and several government-funded grant proposals. In addition to his impressive publication record and broad scientific background, Prof. Miller is an inventor with five patents or patent applications. In addition to his appointment at GWU, Prof. Miller is a Visiting Professor in the Chemical Engineering Department of Cambridge University and is a Bye Fellow of Robinson College, also in Cambridge, England.

Karel Petrak, PhD
Dr. Petrak is President & CEO of PJP Innovations Inc., a consulting company specializing in the pharmaceutical and biotechnology areas and covering all aspects of drug development. His experience working in industry has focused on targeted drug delivery systems using nanoparticles or carbohydrate-based targeting, working with partners in the Texas Medical Center on pre-clinical and clinical aspects of drug development.

Dr. Timothy P. Spicer
Dr. Timothy P. Spicer, an esteemed researcher and Senior Scientific Director at the Department of Molecular Medicine, brings over three decades of experience in drug discovery and biotechnology to ChemoSen3D. Specializing in High Throughput Screening (HTS) technologies, Dr. Spicer’s research aligns with ChemoSen3D’s innovative use of magnetic 3D bioprinting technology for personalized diagnostic testing. His pioneering work in developing 3D spheroid-based ultra-high throughput screening assays dovetails with our commitment to create personalized treatments based on patients’ individual responses. A recipient of prestigious awards and a leader within the Society of Lab Automation and Screening (SLAS), Dr. Spicer’s expertise and collaborative approach will be invaluable to our mission of revolutionizing personalized medicine.

Leonardo Dias, MBA
Leonardo Dias is a seasoned professional with a rich background in finance and business leadership. He holds an MBA in International Finance from The George Washington University and a Bachelor’s degree in Economics from Universidade de Brasília. Leonardo’s career spans over two decades, with significant experience in various roles. He served as the Director at BrScan for over two years and was a Co-Owner for 11 years. Prior to that, he was a Partner at IBET Consulting for nearly a decade and held key positions such as Chief Financial Officer and Investor Relations Officer at Equatorial Energia S.A. His early career includes a six-year stint as Controller and IR Director at Telemig Celular. Leonardo’s extensive experience and academic background make him a valuable addition to ChemoSen3D’s board of directors, where his insights and expertise are expected to contribute significantly to the company’s growth and success.

Deborah Mansfield, MBA
Deborah Mansfield is an innovation business development professional with experience in business acceleration, startup methodology, early business funding, and life science research. In 13+ years as Acceleration Director, legacy Houston Technology Center and beyond, she has served over 500 startups and assisted companies with federal and state funding awards. Her consulting experience includes domestic and international projects for business, economic development, federal funding, and academic education.

William Johnson, MS
Mr. Johnson is the Managing Partner at Boler Biotech Consulting. He has over 25 years’ experience working in the biotechnology and pharmaceutical fields, with previous positions at EMD Millipore, Bullet Biotechnology, Novartis, Wyeth, Broad Institute, Dana-Farber Cancer Institute, Mayo Clinic, Scripps Research Institute, among others.

Hubert Tseng, PhD
Dr. Tseng is a scientist with extensive experience in magnetic 3D bioprinting and applying towards drug discovery and toxicology. Previously a Senior Staff Researcher at the Salk Institute studying the single-cell cytokine secretion of tumor infiltrating immune cells, he is now specializing in immuno-oncology CAR-T product development at Poseida Therapeutics, Inc. Dr. Tseng previously worked in the same position at ChemoSen3D/n3D from 2013-2016. Also, he served as Senior Translational Scientist at Targazyme, advancing their fucosylation pipeline into clinical trials in stem cell transplantation and tumor immunology.

Brad Whitfield, MBA
Brad Whitfield is a Project Management Advisor experienced Business Development and Operations Executive with a global focus and skill set. Also, a tenured Board Member with a demonstrated history of working in the primary/secondary education industry. Skilled in Negotiation, Petroleum, Gas, Operations Management, P&L management and Sales. Mr. Whitfield graduated from Appalachian State University with a Bachelor of Science.